Han Y, et al. - Researchers investigated how mortality and cardiac function in patients with coronary artery disease (CAD) are influenced by metformin. They analyzed 40 studies involving 1,066,408 patients in this systematic review and update meta-analysis. HR was calculated to determine the all-cause mortality, cardiovascular mortality, and incidence of cardiovascular events (CV events), to figure out the level of left ventricular ejection fraction, creatine kinase MB, type B natriuretic peptide and to compare the average level of LDL. Findings revealed a reduction in cardiovascular mortality, all-cause mortality, and CV events in patients with CAD in relation to metformin use. The incidence of CV events was not significantly attenuated by metformin in patients with myocardial infarction and patients with CAD without type II diabetes mellitus. Compared with sulfonylureas, metformin provided a better attenuation in the incidence of CV events.